Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) filed this Current Report on Form 8-K on January 7, 2016. The filing announces unaudited revenue estimates for the fourth quarter and full year ended December 31, 2015, specifically for its product EXPAREL and total company revenue.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the unaudited estimates for Q4 and full-year 2015, but the figures themselves are not included in the provided text.
Material Changes
No specific material changes versus prior periods are detailed in the text of this 8-K. The document serves as a notification that revenue estimates have been issued, with the details contained in the attached press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It also notes that this information is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 7, 2016) for the specific unaudited revenue estimates for EXPAREL and total revenue for Q4 and full-year 2015.
- Verify the company's name change status, as the filing header lists "Pacira Pharmaceuticals, Inc." while the metadata indicates "Pacira Biosciences, Inc."
- Confirm if the unaudited estimates represent a variance from previously issued guidance or analyst expectations.